Five widespread myths about stem cell therapy abroad—instant results, cure claims, one-size-fits-all efficacy, lower safety standards, and unlimited travel eligibility—are contradicted by evidence. Understanding reality reduces disappointment and improves decision-making.
Myth 1: Stem cell therapy produces instant results. Reality: Improvement typically begins weeks to months after treatment, peaks at 3–6 months, and continues to stabilise at 12 months. A patient expecting pain relief or mobility gains immediately post-procedure will be disappointed. Initial post-procedure discomfort often feels like failure, even though it's normal swelling that will resolve. Honest clinics discuss this timeline repeatedly; patients nonetheless often struggle with the psychological gap between treatment completion and noticeable benefit.
Myth 2: Stem cell therapy cures disease. Reality: Current therapies are studied for, reported to reduce symptoms in, or may support regeneration in specific conditions. They do not cure progressive degenerative diseases. A patient with Parkinson's disease may experience slower symptom progression, improved mobility, or reduced tremor—genuine benefits—but disease continues and medications remain necessary. Marketing using 'cure' language is unethical; patients should hear 'improvement in function' or 'slowing progression,' not 'cure.'
Myth 3: Stem cell therapy works equally for everyone. Reality: Response is highly variable. For knee osteoarthritis, 60–75% of patients report meaningful improvement; 25–40% report minimal or no benefit. For neurological conditions, variability is wider. Factors influencing response include age, disease severity, time since onset, cell quality, injection accuracy, and unknown factors. No reliable predictor of individual response exists currently. A clinic claiming >90% success rates is either treating a highly selected population or overstating results.
Myth 4: International clinics have lower safety standards. Reality: Regulatory environments differ, but many international clinics meet or exceed Western standards in practice. Bulgarian clinics accredited by ESGCT or operating under ISO standards often have rigorous protocols. Some international clinics are excellent; others are rogue. The key is vetting individual clinics, not assuming safety by geography. A licensed Bulgarian clinic may be safer than an unaccredited US private clinic. Assumptions based on country alone are misleading.
Myth 5: Anyone can travel and undergo stem cell treatment. Reality: Medical contraindications exist. Active infection, uncontrolled diabetes, certain cancers, severe immunosuppression, and other conditions make stem cell treatment inadvisable or dangerous. Patients should undergo thorough pre-treatment screening. A clinic that accepts all applicants without rigorous evaluation is suspect. Legitimate clinics screen extensively and may decline patients who are unsuitable, even if it costs them revenue. This filtering is a positive sign.
Secondary myth: Stem cell therapy is unproven, so why would I do it? Reality: Stem cell therapy for osteoarthritis has substantial published evidence—dozens of clinical trials, meta-analyses showing 60–75% efficacy. It's not unproven in the way that unproven means useless; it means evidence is emerging and not yet full regulatory approval. For neurological applications, evidence is thinner, and the term 'investigational' is accurate. The distinction matters. A patient can reasonably choose osteoarthritis treatment on current evidence; neurological treatment requires acknowledging higher uncertainty.
Tertiary myth: Cost determines quality. Reality: Price variation reflects overhead and marketing, not purely clinical quality. A clinic charging €5,000 may equal one charging €12,000 in outcomes; the difference is facility location and marketing spend. Conversely, the cheapest clinic may lack rigorous quality control. Sweet spot is typically mid-range with strong independent reviews and transparent outcome reporting—not the cheapest, not the most expensive.
Understanding these myths allows patients to approach treatment with realistic expectations, choose clinics appropriately, and interpret their own outcomes accurately. A patient expecting instant cure from a low-cost clinic will be disappointed; the same treatment at realistic expectations with appropriate clinic selection may be genuinely beneficial.
Educational content; outcomes vary by patient and most uses are investigational — consult a physician. Reviewed by the StemCellAtlas editorial team.
StemCellAtlas is your guide to stem-cell therapy: what the evidence shows, which conditions are treated, and the real all-in cost by country — typically €3,000–8,000 with our partner Stem Plus (Sofia), Europe's lowest-cost EU destination, versus $15,000–35,000 in the US.
Get an honest assessment